2022 Revenues ($USD) : $18,234,986,040.00
2022 Revenues (foreign currencies) : €17,310,600,000
2022 R&D spend : $1,619,075,800.00
2022 Number of Employees : 4,104
Fiscal Year End : 12/31/22
Leader : CEO Uğur Şahin

After allying with Pfizer early in the pandemic, mRNA-specialist BioNTech shipped billions of doses of COVID-19 vaccine across the world in 2021 and 2022. The company brought in nearly €17.3 billion ($18.2 billion) in revenue in 2022, down from €18.9 billion the previous year. The cash generated by its COVID-19 vaccine has enabled BioNTech to advance its oncology pipeline and launch multiple studies, including phase 2 studies related to melanoma, head and neck cancers, multiple solid tumors, and colorectal cancer. In 2023, BioNTech plans to initiate multiple trials with registrational potential. Among these trials are an ongoing open-label phase 2 trial with Genentech, evaluating the efficacy and safety of autogene cevumeran in combination therapies, and the phase 2 IMCODE101 trial, testing RO7198457 and Keytruda against Keytruda alone for patients with previously untreated advanced melanoma. Another phase 2 clinical trial will compare the efficacy of neoantigen-specific immunotherapy RO7198457 versus watchful waiting in patients with ctDNA-positive, resected stage II and stage III colorectal cancer. —BB